uPAR expression was significantly associated with RAS mutational status both in the NSCLC (p < 0.001) and in the CRC cohorts (p < 0.001): 49/98 (50%) RAS mutated NSCLC samples resulted positive for uPAR expression with 33/98 (33.7%) of samples showing strong uPAR expression (score > 3), while only 24/102 (24%) RAS wild-type NSCLC samples showed positivity for uPAR expression with 10/102 (9.8%) of samples achieving IHC score up to 3 (Table 1). The gene discussed is PLAUR; the disease is colorectal carcinoma.